Core Insights - The company Beida Pharmaceutical has signed a strategic cooperation agreement with Hangzhou Ruipu Morning Technology Co., Ltd. to invest in the field of stem cell differentiation technology towards pancreatic cells [2] - The clinical research for RGB-5088, a pancreatic cell injection treatment for Type 1 diabetes developed by Ruipu Morning, is currently in progress [2] - The company will monitor developments in other areas and will disclose any significant collaborations in a timely manner [2]

Group 1 - Company has signed a strategic cooperation agreement with Hangzhou Ruipu Morning Technology Co., Ltd. to invest in the field of stem cell differentiation technology towards pancreatic cells [1] - The clinical research of RGB-5088 pancreatic cell injection for the treatment of type 1 diabetes is currently underway [1] - Company will monitor developments in other areas and will disclose any significant collaborations in a timely manner [1] Group 2 - Company has established a strategic partnership with Shengsi Biotech to enter the hemophilia treatment sector, which is characterized by long-term medication needs and strong customer loyalty [3] - The inquiry from investors highlights the potential for the company to develop long-term medication projects beyond oncology, such as hypertension, diabetes, weight loss, and anti-lipid drugs [3]